Clinical Trial Update: Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase I/II trial of a triple-drug combination (nivolumab, ipilimumab, and nintedanib) for non-small cell lung cancer. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OFEV (Nintedanib)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-25